Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Stomach Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 4Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Adenocarcinoma Of Esophagus 2Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1HER2-expressing Cancers 1HER2-Positive Advanced Biliary Tract Cancer 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Advanced Malignancies 1

Interventions

zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-Positive Advanced Biliary Tract Cancer × zanidatamab × Clear all
NCT04578444 2025-05-25

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Jazz Pharmaceuticals

No longer available
Gastrointestinal

HER2-Positive Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡